

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
February 4, 2015**

**ORDER DENYING CONFIDENTIAL TREATMENT  
REQUEST UNDER RULE 24b-2  
AND  
NOTICE OF OPPORTUNITY TO PETITION  
FOR REVIEW UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

**Orexigen Therapeutics, Inc.**

**File No. 001-33415 - CF#30844**

---

The Division of Corporation Finance has denied your request for an extension of a previous grant of confidential treatment for information excluded from Exhibit 10.1 to the Form 10-Q for the period ended September 30, 2010, as filed on November 4, 2010.

We denied your request because all information excluded from the exhibit for which you had requested an extension of a prior grant of confidential treatment has been publicly disclosed. In particular, after expiration of the previous order granting confidential treatment for information excluded from your exhibit, the subject information was made publicly available pursuant to a request under the Freedom of Information Act ("FOIA"). The FOIA does not permit selective disclosure of information only to certain parties. Once there is disclosure, the information is no longer eligible for a grant of confidential treatment.

If you wish to petition the Commission under 17 C.F.R. 201.430 for review of this order, you must file with the Office of the Secretary (1) a written notice of intention to petition for review within five days after you received this order or otherwise have actual notice of it, and (2) a written petition for review, as described in 17 C.F.R. 201.430(a)(2), within five days thereafter.

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary